



		Q1-2 2006	Q1-2 2005	Change
Revenue	Million EUR	<b>23.2</b>	18.8	23%
Return on revenue before tax	%	<b>9</b>	9	-
EBITDA	Million EUR	<b>4.6</b>	3.9	19%
EBIT	Million EUR	<b>2.4</b>	2.1	13%
EBT	Million EUR	<b>2.2</b>	1.8	23%
Net income before minority interest	Million EUR	<b>1.5</b>	1.0	51%
Net income/loss	Million EUR	<b>1.4</b>	0.9	50%
Earnings per share (basic)	EUR	<b>0.45</b>	0.31	45%
Earnings per share (diluted)	EUR	<b>0.45</b>	0.30	50%
Cash flow from operating activities	Million EUR	<b>1.6</b>	1.2	37%
Depreciation and amortization (net)	Million EUR	<b>2.2</b>	1.8	25%
Employees (as of June 30)	Persons	<b>292</b>	236	24%

Cover page

Large photo (above):

With the Curietron® Remote Afterloading System from Eckert & Ziegler BEBIG cancer on the neck of the uterus, which is particularly common in developing countries, can be healed with minimally, low-side effect brachytherapy.

Small photos to the right (from left to right):

Katrin Antonenko, Director Logistics,  
Eckert & Ziegler BEBIG GmbH, Berlin, Germany  
Joe Hathcock, Chief Operating Officer, Eckert & Ziegler  
Isotope Products Laboratories Inc., Valencia, USA

Small photos (left):

PET/CT scans can detect very small tumor masses.  
Eckert & Ziegler supplies the radioactive tracers for these scans.

Large photo (below):

Many shareholders take the opportunity to find out more about current company developments at the annual general meeting in Berlin.

**Dear Shareholder,**

The upward trajectory of the preceding quarters continued on into the second quarter of 2006. The three-month period of April to June marked the first time that sales reached nearly 12 million EUR, representing a new high-water mark for the Group. Including the already strong first quarter of 2006, half-year results for 2006 show an increase in Group sales of approximately 23% over the first half of 2005, from 18.8 to 23.2 million EUR. A substantial share of this increase, namely around one half or 2.4 million EUR, derives from the new Radiopharmaceuticals segment. A third of the increase, or 1.4 million EUR, comes as expected from the Nuclear Imaging and Industry segment, whose sales potential was considerably strengthened late last year by two acquisitions (Analytics Inc. and Sorad s.r.o.), and for which the reference sources (standards) developed as expected especially well (+114%). In the Therapy segment, sales increased by around 7% over the strong first half of last year, to 8.8 million EUR. Growth in this area was driven by products for treating prostate cancer, which showed an increase of more than 20%.

Profits also continued on an upward trajectory. For the three-month period from April to June, the Group achieved an average return on sales after taxes of 6%. This means that net income after taxes for the first half of the year rose to 1.4 million EUR, which corresponds to a profit per share of 0.45 EUR. Compared to last year's values for the same period (converted to IFRS below) of 0.9 million EUR and 0.30 EUR per share, this represents an increase in profit of approximately 50%. This is the strongest half-year income in the Group's history, because the top figure of 0.52 EUR per share in 2004 derived in large part from the deconsolidation of biotechnology activities. If we compare the half-year income in 2004 (0.4 million EUR) with the current value, earning power has more than tripled over the last two years.

The Nuclear Imaging and Industry segment has played a major role in this encouraging development. It achieved a return on sales of 13% for continuing operations, thus posting a net income of 1.4 million EUR for the first half of the year (last year: 0.5 million EUR). By contrast, the Therapy segment's return on sales reached only 4% for the first half of the year, due in large part to a level of sales that is still too low for current overhead. Because gross sales revenues in the Therapy segment are generally higher than for nuclear imaging and industry products, the Board continues to expect that the profit situation will improve considerably in connection with the anticipated increase in sales volume.

Another factor that contributed strongly to this positive profit performance was the fact that the Radiopharmaceuticals segment incurred considerably lower costs than originally planned, because negotiations with authorization agencies on the design of the clinical study for the rheumatism drug SpondylAT® have been delayed, and thus also the expenditures for said study.

**Milestones**

- Delivery of cancer radiation systems to Venezuela as part of a large-scale contract for basic oncology services
- Successful market introduction of the Modular-Lab™ synthesis module in Germany, Great Britain, and the USA
- The IsoCord® prostate implant receives authorization in France
- Radiodiagnostic contract received at one of the largest nuclear medical centers in Poland, for a volume of 1.3 million EUR
- International user conference in Paris is very well received
- General shareholders' meeting on May 30 attended by holders of around 50% of capital stock.

## Research and Development

In the Therapy segment, efforts are concentrated on developing new applicators and accessory components for existing tumor radiation systems and on optimizing already existing components for further applications. Additional synthesis paths have been developed and documented for the Modular-Lab™ synthesis system (Radiopharmaceuticals segment), including some for substances that can be used to diagnose brain tumors and epilepsy. This family of systems now enables nuclear medical specialists to conveniently produce an even larger number of radiopharmaceuticals for positron emission tomography (PET) scans.

## Staff

The total number of employees throughout the Eckert & Ziegler AG Group increased over the end of 2005, reaching 292 as of 30 June 2006 (31 December 2005: 275). An average of 287 persons was employed over the first half of 2006 (1st half of 2005: 241).

## Outlook

In the aftermath of this successful second quarter of 2006, Eckert & Ziegler AG is optimistic about the further course of the year, and continues to anticipate double-digit increases in both sales and revenue for 2006 as a whole in comparison to last year. Due to the delay in expenditures for the clinical test of the rheumatism drug SpondylAT®, income after taxes in 2006 will presumably surpass the predicted value of 0.70 EUR per share. The level of received orders exceeds that of the year before.

## Balance Sheet

The balance sheet does not show any major changes vis-à-vis the previous quarter. The biggest changes derive from a reduction in liabilities of 0.6 million EUR, and are also evident in the net current assets, which increased by 1.4 million EUR to 7.5 million EUR. The capital ratio rose slightly to 56%.

## Accounting and Valuation Methods

This unaudited Group Interim Report for the second quarter of the 2006 business year comprises the reports from Eckert & Ziegler Strahlen- und Medizintechnik AG and its subsidiaries (also "Eckert & Ziegler AG" below).

Eckert & Ziegler AG's Group Interim Report of 30 June 2006 is published in accordance with IFRS. Group interim reports up to and including those of 2005 were prepared in accordance with the Generally Accepted Accounting Principles valid in the United States of America (US-GAAP). For purposes of comparison, last year's figures included in this Interim Report have been converted in accordance with IFRS.

Eckert & Ziegler AG's Group Interim Report of 30 June 2006 was produced in accordance with the International Financial Reporting Standards (IFRS). It takes into

account all standards stipulated for application in the EU on that date by the International Accounting Standards Board (IASB) in London, as well as official interpretations by the International Financial Reporting Interpretations Committee (IFRIC) and/or the Standing Interpretations Committee (SIC).

The same accounting and valuation methods were applied to the Interim Report as to the Group Financial Statement of 31 December 2005.

To prepare Group interim reports in accordance with IFRS, it is necessary to make estimates and assumptions about the level and extent of the assets, debts, revenues, and expenditures on the balance sheet. The actual values can deviate from the estimates. Major assumptions and estimates are made for useful lives, obtainable revenues from fixed assets, viability of outstanding accounts, and accounting and valuation of provisions.

This Interim Report contains all the information and adjustments needed to acquire a view of the asset, financial, and profit situations of Eckert & Ziegler AG corresponding to actual conditions at the time of the Interim Report. Sub-year results for the ongoing business year cannot necessarily be used to derive conclusions about the development of future results.

### Consolidation Cycle

Eckert & Ziegler AG's Group Interim Report includes all essential companies for which Eckert & Ziegler AG is able to directly or indirectly determine financial and business policy (control function). Between 31 December 2005 and 30 June 2006, there were no changes to the consolidation cycle, so the companies included in the Interim Report of 30 June 2006 are the same as those in the Group Financial Statement of 31 December 2005.

### Currency Conversion

Financial statements for subsidiaries outside the European Currency Union are converted in accordance with the notion of functional currency. A modified closing rate method is applied for all companies. Assets and debts are converted using the average rate on the date of the statement, and equity capital is converted using historical rates. Profit and loss statement items are converted by means of the weighted average rate for the period.

The following exchange rates EUR were used:

Country	Currency	Exchange rate on 30 June 2006	Exchange rate on 30 June 2005	Average rate for the first half of 2006	Average rate for the first half of 2005
USA	US\$	1.255100	1.206600	1.238104	1.284300
Czech Republic	CZK	28.486800	30.110700	28.449502	30.055302

**Significant Events**

No significant events have occurred after the first six months of the 2006 business year.

**Limited Comparability of this Group Interim Report with Last Year**

Eckert & Ziegler AG and/or its subsidiaries acquired a number of companies during the 2005 business year. This substantially affected the Group's asset and profit situations, which makes it difficult to compare this Group Interim Report with that of last year.

**Dividends Paid**

Dividends amounting to EUR 469,164.75 were paid in the second quarter of 2006. This corresponds to a dividend per share of EUR 0.15.

**Number of Own Shares**


As of 30 June 2006, Eckert & Ziegler AG held 122,235 of its own shares.



Dr. Andreas Eckert,  
Chief Executive Officer



Dr. Edgar Löffler,  
Executive Vice President



Dr. Andreas Hey,  
Executive Vice President

Berlin, July 28, 2006

	<b>Quarterly report II/2006 04–06/2006</b>	Quarterly report II/2005 04–06/2005	<b>6-monthly report 2006 01–06/2006</b>	6-monthly report 2005 01–06/2005
	TEUR	TEUR	TEUR	TEUR
<b>Revenue</b>	<b>11,892</b>	10,234	<b>23,176</b>	18,811
Others	-			
Cost of goods sold	<b>-5,784</b>	-5,376	<b>-11,914</b>	-10,592
<b>Gross profit on sales</b>	<b>6,108</b>	4,858	<b>11,262</b>	8,219
Selling expenses	<b>-2,120</b>	-1,516	<b>-4,172</b>	-2,839
General and administrative expenses	<b>-2,610</b>	-2,143	<b>-5,107</b>	-3,917
Research and development expenses	<b>-163</b>	-94	<b>-266</b>	-170
Other operating income	<b>329</b>	140	<b>865</b>	373
Other operating expense	<b>-231</b>	-6	<b>-247</b>	-10
<b>Operating income/loss</b>	<b>1,313</b>	1,239	<b>2,336</b>	1,656
Interest receivable and payable, net	<b>-255</b>	-155	<b>-391</b>	-240
Gains/losses on currency exchange, net	<b>32</b>	38	<b>-15</b>	337
Other income/expense, net	<b>95</b>	-	<b>228</b>	-
<b>Income before tax and minority interest</b>	<b>1,185</b>	1,122	<b>2,157</b>	1,753
Income tax expense	<b>-341</b>	-565	<b>-617</b>	-732
<b>Net income/loss before minority interest</b>	<b>844</b>	557	<b>1,540</b>	1,021
Share of profit (-) / or loss (+) attributable to minority interest	<b>-75</b>	-74	<b>-121</b>	-74
<b>Net income/loss</b>	<b>769</b>	483	<b>1,419</b>	947
<b>Earnings per share (basic)</b>	<b>0.25</b>	0.16	<b>0.45</b>	0.31
<b>Earnings per share (diluted)</b>	<b>0.24</b>	0.15	<b>0.45</b>	0.30
Average number of shares in circulation (basic)	<b>3,123</b>	3,093	<b>3,123</b>	3,091
Average number of shares in circulation (diluted)	<b>3,158</b>	3,140	<b>3,158</b>	3,130

	June 30, 2006	Dec 31, 2005
	TEUR	TEUR
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	17,779	18,501
Intangible assets	7,087	6,994
Goodwill	11,171	11,681
Equity investments	68	68
Deferred taxes	4,047	3,985
Other non-current assets	2,016	1,860
<b>Total non-current assets</b>	<b>42,168</b>	43,089
<b>Current assets</b>		
Cash and cash equivalents	4,023	4,950
Marketable securities	1,631	2,444
Trade accounts receivable, less allowance for doubtful accounts	9,343	9,499
Receivables from related parties	12	13
Inventories	5,945	6,029
Prepaid expenses and other current assets	908	973
<b>Total current assets</b>	<b>21,862</b>	23,908
<b>Total assets</b>	<b>64,030</b>	66,997
<b>EQUITY AND LIABILITIES</b>		
<b>Shareholders' equity</b>		
Subscribed capital	3,250	3,250
Capital reserve	29,471	29,346
Retained earnings	5,266	4,316
Cumulative other comprehensive income	-2,258	-1,623
Own shares	-409	-434
Minority interests	221	100
<b>Total shareholders' equity</b>	<b>35,541</b>	34,955
<b>Non-current liabilities</b>		
Long-term debt, less current portion and capital lease obligations	9,983	9,316
Deferred income from grants and other deferred income	1,308	1,841
Deferred taxes	2,452	2,563
Pension reserves	133	128
Other non-current liabilities	3,627	3,755
<b>Total non-current liabilities</b>	<b>17,503</b>	17,603
<b>Current liabilities</b>		
Short-term debt and current portion of long-term debt and capital lease obligations	1,881	3,437
Trade accounts payable	3,188	4,162
Prepayments received	16	55
Accrued expenses	2,917	3,236
Deferred income from grants and other deferred income	932	939
Income tax payable	387	592
Other current liabilities	1,665	2,018
<b>Total current liabilities</b>	<b>10,986</b>	14,439
<b>Total liabilities and shareholders' equity</b>	<b>64,030</b>	66,997



	<b>6-monthly report</b> <b>01 – 06/2006</b>	6-monthly report 01 – 06/2005
	TEUR	TEUR
<b>Cash flows from operating activities</b>		
Net income/loss	<b>1,419</b>	947
Adjustments for:		
Depreciation and amortization	<b>2,233</b>	1,782
Proceeds from grants		
less release of deferred income from grants	<b>-533</b>	-505
Deferred taxes	<b>-86</b>	441
Income (-)/expense from stock option plan	<b>53</b>	42
Unrealized foreign currency gains (-)/losses	<b>258</b>	-56
Long-term reserves, other long-term liabilities	<b>-19</b>	309
Gains (-) / losses (+) on the disposal of non-current assets	<b>10</b>	1
Gains (-) / losses (+) on the sale of securities	<b>-25</b>	0
Other items, net	<b>-40</b>	15
Changes in current assets and liabilities:		
Receivables	<b>619</b>	-1,004
Inventories	<b>-24</b>	-505
Prepaid expenses and other current assets	<b>85</b>	59
Accounts payable and accounts payable to affiliates	<b>-1,200</b>	638
Tax reserves	<b>-246</b>	-76
Other liabilities	<b>-868</b>	-895
<b>Net cash generated from operating activities</b>	<b>1,636</b>	1,193
<b>Cash flows from investing activities</b>		
Additions to / Sale of non-current assets	<b>-2,082</b>	-1,276
Acquisitions of consolidated enterprises	-	-123
Sale of securities	<b>826</b>	-801
Other items	-	-13
<b>Net cash used in investing activities</b>	<b>-1,256</b>	-2,213
<b>Cash flows from financing activities</b>		
Dividends paid	<b>-469</b>	-775
Change in long-term borrowing	<b>-877</b>	-246
Change in short-term borrowing	<b>64</b>	224
Treasury stock used for stock options	<b>97</b>	133
<b>Net cash generated from financing activities</b>	<b>-1,185</b>	-664
Effect of exchange rates on cash and cash equivalents	<b>-122</b>	127
<b>Decrease/increase in cash and cash equivalents</b>	<b>-927</b>	-1,557
<b>Cash and cash equivalents at beginning of period</b>	<b>4,950</b>	5,504
<b>Cash and cash equivalents at end of period</b>	<b>4,023</b>	3,947



**01 – 06/2006**

	<b>Nuclear Medicine &amp; Industry</b>	<b>Therapy</b>	<b>Radio- pharma- ceuticals</b>	<b>Others</b>	<b>Consoli- dation</b>	<b>Totals</b>
	TEUR	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	11,997	8,771	2,408			23,176
Sales to other segments	415	57	7	339	-818	
<b>Total segment sales</b>	<b>12,412</b>	<b>8,828</b>	<b>2,415</b>	<b>339</b>	<b>-818</b>	<b>23,176</b>
Depreciation & amortization	-658	-1,233	-263	-79		-2,233
Net income/loss before minority interest	1,358	336	33	-187		1,540
Segmental assets	27,370	19,598	10,005	38,343	-31,286	64,030
Segmental liabilities	-14,867	-19,223	-10,112	-5,117	20,830	-28,489
Capital expenditure	350	1,595	130	8		2,082

**Sales by geographic areas 01 – 06/2006**

	Mio EUR	%
North America	9.2	40
Europe	11.6	50
Asia/Pacific	0.9	4
Others	1.5	6
	23.2	100

**01 – 06/2005**

	<b>Nuclear Medicine &amp; Industry</b>	<b>Therapy</b>	<b>Others</b>	<b>Consoli- dation</b>	<b>Totals</b>
	TEUR	TEUR	TEUR	TEUR	TEUR
Sales to external customers	10,612	8,198	1		18,811
Sales to other segments	116	92	291	-499	
<b>Total segment sales</b>	<b>10,728</b>	<b>8,290</b>	<b>292</b>	<b>-499</b>	<b>18,811</b>
Depreciation & amortization	-656	-1,069	-59	1	-1,783
Net income/loss before minority interest	521	448	-22		947
Segmental assets	29,163	20,238	34,775	-27,522	56,654
Segmental liabilities	-12,026	-14,489	-2,054	17,669	-10,900
Capital expenditure	281	965	1		1,247

**Sales by geographic areas 01 – 06/2005**

	Mio EUR	%
North America	8.8	47
Europe	8.8	47
Asia/Pacific	1.2	6
Others	0.0	<1
	18.8	100

<b>Management Board and Supervisory Board</b>		<b>June 30, 2006</b>	
		Stocks	Stock Options
Dr. Andreas Eckert (Eckert Consult GmbH)	Management Board	2,100 (1,230,446)	18,500 (0)
Dr. Andreas Hey	Management Board	0	6,000
Dr. Edgar Löffler	Management Board	10,250	22,000
Prof. Dr. Wolfgang Maennig	Supervisory Board	0	0
Prof. Dr. Ronald Frohne	Supervisory Board	0	0
Hans-Jörg Hinke	Supervisory Board	0	0
Ralf Hennig	Supervisory Board	141	0
Frank Perschmann	Supervisory Board	1,000	0
Prof. Dr. Nikolaus Fuchs	Supervisory Board	0	0

### Financial Calendar

#### August 08, 2006

Quarterly Report II/2006

#### November 07, 2006

Quarterly Report III/2006

#### November 29, 2006

German Equity Forum in Frankfurt

#### March 29, 2007

Annual Report 2006

#### March 29, 2007

Balance Press Conference in Berlin

#### April 17, 2007

Medtech Day in Frankfurt

#### May 08, 2007

Quarterly Report I/2007

#### June 12, 2007

Annual General Meeting in Berlin

#### August 07, 2007

Quarterly Report II/2007

#### November 06, 2007

Quarterly Report III/2007

#### November 2007

German Equity Forum in Frankfurt

### Eckert & Ziegler

### Strahlen- und Medizintechnik AG

Robert-Rössle-Str. 10

D-13125 Berlin

www.ezag.de

Telephone +49 (0) 30 94 10 84 - 0

Telefax +49 (0) 30 94 10 84 - 112

e-mail info@ezag.de

ISIN DE 0005659700

WKN 565 970